A ranar 29 ga Janairu, 2025, wata ƙungiyar bincike ta ƙasar Sin ta buga wani kasida mai taken "Neoadjuvant pyrotinib da trastuzumab a cikin HER2 positive nono cancer without response da wuri (NeoPaTHer): tasiri, aminci, da kuma nazarin alamar halitta na wani bincike mai yiwuwa, mai cibiya da yawa, wanda aka daidaita da martani" a cikin mujallar "Siginar Transduction da Targeted Therapy".
Ciwon daji na nono mai siffar 2 (HER2) wanda ke da alhakin kusan kashi 15% zuwa 25% na dukkan ciwon daji na nono, an san shi a matsayin wani nau'in ciwon daji na musamman da ke da tsauri. Ana siffanta shi da yawan HER2, wani mai karɓar transmembrane tyrosine kinase wanda ke haɓaka yaɗuwar ƙwayoyin cutar kansa da rayuwa. Marasa lafiya da ke da ciwon daji na HER2 mai siffar 2 suna fuskantar haɗarin sake dawowa da mutuwa idan aka kwatanta da waɗanda ke da wasu nau'ikan ciwon daji na nono, wanda hakan ya sa ya zama cuta mai ƙalubale a yi maganinta. Duk da haka, yanayin maganin ciwon daji na HER2 mai siffar 2 ya sami sauyi mai ban mamaki a cikin shekaru ashirin da suka gabata, musamman saboda gabatar da magungunan da aka yi niyya ga HER2. Musamman ma, zuwan trastuzumab ya canza yanayin ciwon daji na HER2 mai siffar 2 daga wata cuta mai matuƙar kisa zuwa wata wadda ke da sakamako mafi sauƙi kuma mara tsanani.
Tsakanin Oktoba 2020 da Maris 2022, jimillar marasa lafiya 129 daga asibitoci biyar ne aka yi rajista a cikin wannan binciken. Daga cikin marasa lafiya 129 da aka yi rajista, an gano 62 (48.1%) a matsayin masu amsa MRI (ƙungiya A), waɗanda ba sa amsawa 26 sun ci gaba da yin zagaye huɗu na TCbH (ƙungiya B), kuma waɗanda ba sa amsawa 41 sun sami ƙarin pyrotinib (ƙungiya C). Adadin tpCR ya kasance 30.6% (95% CI: 20.6–43.0%) a cikin rukunin A, 15.4% (95% CI: 6.2–33.5%) a cikin rukunin B, da 29.3% (95% CI: 17.6–44.5%) a cikin rukunin C. Binciken juzu'i na logistic mai canzawa da yawa ya nuna daidaito iri ɗaya na cimma tpCR tsakanin ƙungiyoyin A da C (rabo mara kyau = 1.04, 95% CI: 0.40–2.70). Ba a lura da sabbin abubuwan da suka faru ba tare da ƙara pyrotinib. Marasa lafiya da ke da haɗin gwiwa na TP53 da PIK3CA sun nuna ƙarancin martanin farko idan aka kwatanta da waɗanda ba su da ko tare da maye gurbin kwayar halitta guda ɗaya (36.0% vs. 60.0%, P = 0.08). Waɗannan binciken sun nuna cewa ƙara pyrotinib na iya amfanar marasa lafiya waɗanda ba sa amsawa ga neoadjuvant trastuzumab plus chemotherapy. Ana buƙatar ƙarin bincike don gano alamun biomarkers da ke hasashen fa'idar marasa lafiya daga ƙarin pyrotinib.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Nassoshi
https://www.nature.com/articles/s41392-025-02138-6
Lokacin Saƙo: Fabrairu-08-2025